Our Pricing

Mounjaro to Wegovy Switch: Complete UK Clinical Guide & Cost Comparison

Making a mounjaro to wegovy switch is one of the most common transitions we support at Cured Pharmacy, typically driven by cost considerations or supply constraints. Both medications deliver clinically proven weight loss, but switching from tirzepatide (Mounjaro) to semaglutide (Wegovy) requires careful dose mapping to maintain therapeutic effect whilst minimising side effects. Our UK-registered clinical team has guided thousands of patients through this transition, ensuring continuity of care under full prescriber supervision.

Why Patients Consider a Mounjaro to Wegovy Switch

The primary driver for a mounjaro to wegovy switch in the UK is cost savings. At Cured Pharmacy, Wegovy starts from £124.99 per month compared to Mounjaro at £124.99 representing a saving of £124.99 monthly or £124.99 annually. For patients on long-term weight management programmes, this difference becomes substantial whilst maintaining access to a GLP-1 receptor agonist with robust clinical evidence.

Supply availability also influences switching decisions. Wegovy has demonstrated more consistent UK stock levels in recent months, and some patients prefer the established NHS pathway for semaglutide. Clinical outcomes remain strong with both medications—STEP trials showed semaglutide achieved average weight loss of 15-17% body weight, whilst SURPASS trials demonstrated tirzepatide achieved 15-22% depending on dose[1]. Both require ongoing prescriber oversight and are dispensed only following clinical assessment by our UK-registered team.

Clinical Dose Mapping for Mounjaro to Wegovy Switch

When switching from mounjaro to wegovy, direct milligram-to-milligram conversion is not appropriate because tirzepatide and semaglutide have different pharmacological potencies. Patients on Mounjaro 7.5mg are typically transitioned to Wegovy 1.7mg or 2.4mg, depending on individual response and tolerability. Our prescribers assess weight loss trajectory, side effect history, and treatment duration before recommending the equivalent Wegovy dose.

The transition does not require a washout period. Mounjaro has a half-life of approximately five days, so most prescribers recommend starting Wegovy one week after the final Mounjaro injection to avoid overlapping GLP-1 activity. This approach minimises gastrointestinal side effects whilst maintaining therapeutic drug levels[2]. Every mounjaro to wegovy switch at Cured Pharmacy includes a personalised clinical review by our superintendent pharmacist Tarun Kumar (GPhC 2233073) or a prescribing clinician to ensure safe, evidence-based care.

Recommended Dose Equivalence

For patients on Mounjaro 7.5mg, the clinically comparable Wegovy dose is typically 1.7mg or 2.4mg. If you experienced good tolerance and weight loss on Mounjaro 7.5mg, transitioning to Wegovy 2.4mg often maintains momentum. If you experienced significant nausea or gastrointestinal upset, starting at Wegovy 1.7mg allows for gentler adaptation, with the option to titrate to 2.4mg after four weeks under prescriber guidance[3]. All dose decisions are made during your free online consultation.

What to Expect During Your Mounjaro to Wegovy Switch

Most patients report a smooth mounjaro to wegovy switch with minimal disruption to weight loss progress. Semaglutide and tirzepatide share the same GLP-1 receptor agonist mechanism, so appetite suppression and satiety effects continue. Some patients notice a temporary plateau in the first two weeks as the body adjusts to the new medication, but weight loss typically resumes as Wegovy reaches steady-state plasma concentration after four to five weeks[4].

Gastrointestinal side effects—nausea, constipation, or mild diarrhoea—may re-emerge during the switch, particularly if transitioning to Wegovy 2.4mg. These effects are usually transient and resolve within one to two weeks. We advise patients to maintain adequate hydration, eat smaller meals, and avoid high-fat foods during the transition period. If side effects persist beyond three weeks, our clinical team can adjust the dose or provide tailored management strategies.

Cost Savings: Mounjaro to Wegovy Switch Financial Comparison

Switching from mounjaro to wegovy delivers immediate monthly savings of £124.99 at Cured Pharmacy's pricing. Over a 12-month weight loss programme, this equates to £124.99 in total savings whilst maintaining access to a clinically proven GLP-1 medication. New patients also benefit from £20 off their first order using code Weightlossnew, reducing the initial Wegovy cost to just £124.99.

Wegovy's lower cost does not reflect inferior efficacy—both medications are MHRA-licensed and NICE-appraised for chronic weight management. The price difference stems from market competition and supply dynamics rather than clinical performance. Patients switching for financial reasons can be confident they are receiving the same standard of UK pharmaceutical care, with all prescriptions reviewed by our GPhC-registered clinical team and dispensed from our licensed pharmacy (GPhC 9012511).

Transparent Pricing Before Consultation

At Cured Pharmacy, all prices are displayed upfront before you begin your clinical assessment. There are no hidden fees, and your total cost is confirmed before payment. Wegovy from £124.99 includes the medication, prescriber review, and discreet next-day delivery across the UK. This transparency is central to our commitment to accessible, affordable weight management care.

How to Switch from Mounjaro to Wegovy with Cured Pharmacy

Starting your mounjaro to wegovy switch is straightforward. Complete our free online consultation (under three minutes), where you'll provide details of your current Mounjaro dose, treatment duration, weight loss progress, and any side effects. Our UK-registered prescriber reviews your assessment and determines the appropriate Wegovy starting dose. If approved, your prescription is dispensed the same day and dispatched via next-day delivery in 100% discreet packaging.

You do not need to see your NHS GP to switch between private weight loss medications, though we always encourage keeping your GP informed of any ongoing treatments. Our clinical team liaises with your existing prescriber if necessary to ensure continuity of care. Repeat prescriptions are managed seamlessly through your Cured Pharmacy account, with automatic reminders so you never miss a dose.

Mounjaro to Wegovy Switch: Long-Term Weight Maintenance

Successful weight loss is only the first phase—long-term maintenance requires sustained medication adherence and lifestyle modification. Clinical trials show that patients who discontinue GLP-1 therapy typically regain two-thirds of lost weight within one year[5]. Switching from mounjaro to wegovy allows cost-effective continuation of therapy without compromising clinical outcomes, supporting durable weight management.

Our clinical team recommends regular weight monitoring, quarterly prescriber reviews, and integration of dietary and physical activity changes alongside Wegovy. The medication is licensed for chronic use, and many patients remain on semaglutide for two years or longer under ongoing medical supervision. Cured Pharmacy provides continuity of care throughout your weight loss journey, with the same prescribing team managing your treatment from initial consultation through maintenance.

Ongoing Clinical Support

Every patient switching from mounjaro to wegovy receives access to our UK clinical team for questions, dose adjustments, or side effect management. You can contact us via phone (+44 116 4646009) or through your secure patient account. Our pharmacists and prescribers are available to support your transition and optimise your treatment plan based on real-world response.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 29(10), 2473-2481. [accessed 15 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.